Ionis Pharmaceuticals (IONS) Other Accumulated Expenses (2016 - 2026)

Ionis Pharmaceuticals' Other Accumulated Expenses history runs 11 years deep, the most recent figure standing at $23.4 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 4.87% year-over-year to $23.4 million; the TTM figure through Mar 2026 stood at $23.4 million (up 4.87% YoY), while the FY2025 annual figure was $28.3 million, up 45.34% from the prior year.
• Other Accumulated Expenses was $23.4 million for Q1 2026 at Ionis Pharmaceuticals, down from $28.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $28.3 million in Q4 2025 to a low of $7.5 million in Q4 2022.
• Historically, Other Accumulated Expenses has averaged $16.7 million across 5 years, with a median of $17.1 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses plunged 38.81% in 2022, then soared 123.31% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $7.5 million in 2022, then rose by 17.2% to $8.8 million in 2023, then soared by 120.38% to $19.5 million in 2024, then soared by 45.34% to $28.3 million in 2025, then retreated by 17.31% to $23.4 million in 2026.
• The last three Other Accumulated Expenses figures came in at $23.4 million (Q1 2026), $28.3 million (Q4 2025), and $24.8 million (Q3 2025), per Business Quant data.